Contents

BREAKING ADVANCES
4595  Highlights from Recent Cancer Literature

OBITUARY
4597  Emil Frei III, MD: In Memoriam (1924–2013)

REVIEWS
4599  A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
Nicholas Mitsiades

4606  Myeloid-Derived Suppressor Cells as Osteoclast Progenitors: A Novel Target for Controlling Osteolytic Bone Metastasis
Anandi Sawant and Selvarangan Ponnazhagan

PERSPECTIVE
4611  Cancer Research Advocacy: Past, Present, and Future
Jane Perlmutter, Shannon K. Bell, and Gwen Darien

INTEGRATED SYSTEMS AND TECHNOLOGIES
4616  Quantitative In Vivo Characterization of Intracellular and Extracellular pH Profiles in Heterogeneous Tumors: A Novel Method Enabling Multiparametric pH Analysis
Norbert W. Lutz, Yann Le Fur, Johanna Chiche, Jacques Pouyssegur, and Patrick J. Cozzone

MICROENVIRONMENT AND IMMUNOLOGY
4629  Tumor Promotion by Intratumoral Plasmacytoid Dendritic Cells Is Reversed by TLR7 Ligand Treatment
Isabelle Le Mercier, Dominique Poujol, Amélie Sanlaville, Vanja Sisirak, Michael Gobert, Isabelle Durand, Bertrand Dubois, Isabelle Treilleux, Jacqueline Marvel, Jaromir Vlach, Jean-Yves Blay, Nathalie Bendriss-Vermare, Christophe Caux, Isabelle Puisieux, and Nadège Goutagny

Précis: This study suggests a new use in breast cancer treatment for synthetic ligands of TLR7 like imiquimod that are used widely as immunomodulators in clinic.

4641  Vaccine-Instructed Intratumoral IFN-γ Enables Regression of Autochthonous Mouse Prostate Cancer in Allogeneic T-Cell Transplantation
Rodrigo Hess Michelini, Teresa Manzo, Tabea Sturmheit, Veronica Basso, Martina Rocchi, Massimo Freschi, Joanna Listopad, Thomas Blankenstein, Matteo Bellone, and Anna Mondino

Précis: Findings argue that cancer vaccines that improve antitumor T-cell responses can cooperate strongly with allogeneic bone marrow transplants to convert them into effective treatments for solid tumors.

4663  Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab
Diane Goërè, Caroline Flamant, Sylvie Busakiewicz, Vichnou Poirier-Colame, Oliver Kepp, Isabelle Martinis, Julien Pesquet, Alexander Eggermann, Dominique Elias, Nathalie Chaput, and Laurence Zitvogel

Précis: This study reports a comprehensive dissection of the immunomodulatory effects of a bispecific mAb specific for a widely expressed tumor cell adhesion molecule and the T-cell molecule CD3, which is one of the first bispecific mAbs to be explored in clinic.
Histone Demethylase RBP2 Promotes Lung Tumorigenesis and Cancer Metastasis
Yu-Ching Teng, Cheng-Feng Lee, Ying-Shiuan Li, Yi-Ren Chen, Pei-Wen Hisiao, Meng-Yu Chhan, Feng-Mao Lin, Hsien-De Huang, Yen-Ting Chen, Yang-Ming Jeng, Chih-Hung Hsu, Qin Yan, Ming-Daw Tsai, and Li-Jung Juan

Precise: Findings establish an oncogenic function in lungs for an Rb binding protein that modifies chromatin, with implications for malignant progression in this tissue.

Proteomic and Lipidomic Signatures of Lipid Metabolism in NASH-Associated Hepatocellular Carcinoma
Kyle Muir, Antoniouk Hazim, Ying He, Marion Peyressatre, Do-Young Kim, Xiaolong Song, and Laura Beretta

Precise: This study reveals a role for lipid-modifying enzymes in liver cancer, identifying in particular a specific type of long-chain polyunsaturated fatty acid participating in nonalcoholic steatohepatitis and liver cancer risk.

Posttranscriptional Regulation of PER1 Underlies the Oncogenic Function of IRE1α

Precise: Circadian rhythms that may affect chemotherapeutic efficacy are linked here for the first time to the unfolded protein response, a signaling pathway widely activated in cancer that plays an important role in tumor aggressiveness.

Peroxiredoxin-2 Represses Melanoma Metastasis by Increasing E-Cadherin/β-Catenin Complexes in Adherens Junctions
Doo Jae Lee, Dong Hoon Kang, Mina Choi, Yang Ji Choi, Joo Young Lee, Joo Hyun Park, Yoon Jung Park, Kyung Wha Lee, and Sang Won Kang

Precise: In discovering a specific antioxidant enzyme that can repress melanoma metastasis, this study also suggests a tractable new direction to treat this deadly disease.

TR3 Modulates Platinum Resistance in Ovarian Cancer
Andrew J. Wilson, Annie Y. Liu, Joseph Roland, Oluwafunmilayo B. Adebayo, Sarah A. Fletcher, James C. Slaughter, Jeanette Saskowski, Marta A. Crispens, Howard W. Jones III, Samuel James, Oluwade Fadare, and Dineo Khabele

Precise: There remains great interest in determining general strategies to overcome resistance to platinum compounds that are used very widely to treat cancer, including ovarian cancer.
GENETIC ABLATION OF THE FATTY ACID-BINDING PROTEIN FABP5 SUPPresses HER2-Induced Mammary Tumorigenesis
Liraz Levi, Glenn Lobo, Mary Kathryn Doud, Johannes von Lintig, Darcie Seachrist, Gregory P. Tochtrup, and Noa Noy

PRES: A protein that delivers fatty acids to the transcription factor PPARY/β/δ is critical for mammary tumor development, rationalizing the development of FABP5 inhibitors to prevent or treat breast cancer.

4781
PanIN-Specific Regulation of Wnt Signaling by HIF2α during Early Pancreatic Tumorigenesis
Angela Criscimanna, Li-Juan Duan, Julie A. Rhodes, Volker Fendrich, Emily Wickline, Douglas J. Hartman, Satdarshan P.S. Monga, Michael T. Lotze, George K. Gittes, Guo-Hua Fong, and Farzad Esni

PRES: This study identifies root signaling connections between hypoxia control and the Wnt and Smad4 pathways in early development of pancreatic cancer.

4791
Enhanced Radiation Sensitivity in HPV-Positive Head and Neck Cancer

PRES: Activation of residual p53 in HPV+ head and neck cancers may explain why this type of disease has a relatively better outcome in patients.

PREVENTION AND EPIDEMIOLOGY

4801
Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer
Yan Wang, Jian Gu, Jack A. Roth, Michelle A.T. Hildebrandt, Scott M. Lippman, Yuanqing Ye, John D. Minna, and Xifeng Wu

PRES: Accumulating evidence argues that microRNA signatures derived from blood serum may offer simple quantitative tools for clinical prognosis and therapeutic development in many settings.

4810
A 20-Year Prospective Study of Plasma Prolactin as a Risk Marker of Breast Cancer Development
Shelley S. Tworoger, A. Heather Eliassen, Xuehong Zhang, Jing Qian, Patrick M. Sless, Bernard A. Rosner, and Susan E. Hankinson

PRES: Elevated levels of plasma prolactin are associated with an increased risk of breast cancer, but only for 10 years after assessment of this risk marker, supporting a role for prolactin at later stages in breast carcinogenesis.

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

4820
Novel Recombinant Human B7-H4 Antibodies Overcome Tumoral Immune Escape to Potentiate T-Cell Antitumor Responses
Denarda Dangaj, Evripidis Lanitis, Aizhi Zhao, Shree Joshi, Yi Cheng, Raphael Sandaltzopoulos, Hyun-Jeong Ra, Gwenn Danet-Desnoyers, Daniel J. Powell, Jr, and Nathalie Scholler

PRES: Blockade of inhibitory T-cell receptor signals in the same general family as the CTLA-4 molecule targeted by ipilimumab (Yervoy) may offer a paradigm for simultaneous targeting of not only tumor cells, but also tumor-associated macrophages that drive immune escape.

4830
Transcription Poisoning by Topoisomerase I Is Controlled by Gene Length, Splice Sites, and miR-142-3p
Stéphanie Solier, Michael C. Ryan, Scott E. Martin, Sudhir Varma, Kurt W. Kohn, Hongfang Liu, Barry R. Zeeberg, and Yves Pommier

PRES: Camptothecins used in cancer therapy may act to a major extent by targeting a p53-dependent microRNA.

4840
C-RAF Mutations Confer Resistance to RAF Inhibitors
Rajee Antony, Caroline M. Emery, Allison M. Sawyer, and Levi A. Garraway

PRES: These findings may provide a rationale for the future development of allosteric or pan-RAF inhibitors that disrupt the RAF dimerization interface.

4850
Pivotal Role of the Lipid Raft SK3–Orai1 Complex in Human Cancer Cell Migration and Bone Metastases

PRES: This study links a therapeutically targetable potassium channel to bone metastasis, a common feature of advanced breast and prostate cancers that is generally untreatable.

4860
Docetaxel Conjugate Nanoparticles That Target α-Smooth Muscle Actin–Expressing Stromal Cells Suppress Breast Cancer Metastasis
Mami Murakami, Mark J. Ernsting, Eliusz Undzys, Nathan Holwell, Warren D. Foltz, and Shyh-Dar Li

PRES: A novel cytotoxic nanoparticle that specifically degrades stromal elements in the tumor microenvironment exhibits potent antitumor activity.
Expression in Malignant Germ Cell Tumors Downregulates let-7 and Increases Oncogene Levels

Precise: This study defines a common oncogenic pathway in malignant germ cell tumors (GCT) and offers preclinical initial proof of concept for its targeting potential in this setting.

A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
Xiaomei Zhang, Sofie Claerhout, Aleix Pratt, Lacey E. Dobrolecki, Ivana Petrovic, Qing Lai, Melissa D. Landis, Lisa Wierchmann, Rachel Schaff, Mario Giuliano, Helen Wong, Suzanne W. Fuqua, Alejandra Contreras, Carolina Gutierrez, Jian Huang, Sufeng Mao, Anne C. Pavlick, Amber M. Froehlich, Meng-Fen Wu, Anna Tsimelzon, Susan G. Hilsenbeck, Edward S. Chen, Pavel Zuloaga, Chad A. Shaw, Charles M. Perou, Gordon B. Mills, Jenny C. Chang, and Michael T. Lewis

Precise: This work illustrates a general method to prospectively isolate tumor-initiating cells, the imaging and targeting of which may be important for improving therapeutic outcomes in individual patients.

eIF4B Phosphorylation by Pim Kinases Plays a Critical Role in Cellular Transformation by Ab1 Oncogenes
Jianling Yang, Jun Wang, Ke Chen, Guijie Guo, Ruijiao Xi, Paul B. Rothman, Douglas Whitten, Lianfeng Zhang, Shile Huang, and Ji-Long Chen

Precise: Results identify the translation initiation factor eIF-4B as a critical substrate of Pim kinases, which mediate the activity of Ab1 oncogenes, suggesting this factor as a candidate therapeutic target in Ab1-induced cancers.

Canonical Wnt Signaling Is Required for Pancreatic Carcinogenesis
Yaqing Zhang, John P. Morris IV, Wei Yan, Heather K. Schofield, Austin Gurney, Diane M. Simeone, Sarah E. Millar, Timothy Hoey, Matthias Hebrak, and Marina Pasca di Magliano

Precise: This study establishes a causal role for WNT pathway signaling in the development and progression of K-ras-initiated pancreatic cancers, with therapeutic implications for the use of WNT pathway antagonists in this deadly disease.

Retraction: Sp100 as a Potent Tumor Suppressor: Accelerated Senescence and Rapid Malignant Transformation of Human Fibroblasts through Modulation of an Embryonic Stem Cell Program

CORRECTION: IKK4a/ARF Inactivation with Activation of the NF-kB/IL-6 Pathway Is Sufficient to Drive the Development and Growth of Angiosarcoma

ABOUT THE COVER

Schematic representation of the IRE1α-dependent activation loop that controls tumor cell adaptation. Tumor cell is presented in light gray, stromal cells in dark gray. Proteins are represented by circles, with upregulation in green and downregulation in red. Connections following stress-mediated activation of IRE1α are presented in green for activation and red for inhibition. For details, see article by Pluquet and colleagues on page 4732.